Pharmaceutical care of a case of carbapenem resistant Klebsiella pneumoniae bloodstream infection treated with ceftazidime/verbatan

doi:10.19803/j.1672-8629.20210178

Abstract

Abstract: Objective To investigate the role of clinical pharmacists in the treatment of bloodstream infection caused by carbapenem resistant Klebsiella pneumoniae. Methods Clinical pharmacists participated in the treatment of a patient with bloodstream infection caused by carbapenem resistant Klebsiella pneumoniae. Based on their expertise and the condition of the patient, the pharmacists recommended ceftazidime/avibactam monotherapy, and monitored the effectiveness and safety of medication. Results The clinicians took the advice of clinical pharmacists so that the patient’s temperature returned to normal, the inflammatory indexes were improved, and the blood culture showed no bacterial growth. Conclusion By participating in clinical practice, clinical pharmacists can quickly learn about the usage of new drugs, provide pharmaceutical services for clinicians, and ensure the rationality and safety of drug use.

Key words: Klebsiella pneumoniae, carbapenem resistant, ceftazidime/avibactam, pharmaceutical care

CLC Number:

R969.3

REN Zhao, LIU Jia, WANG Yumin, WANG Yue, XIE Qing. Pharmaceutical care of a case of carbapenem resistant Klebsiella pneumoniae bloodstream infection treated with ceftazidime/verbatan[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1258-1261.

References

[1] POURNARAS S, PROTONOTARIOU E, VOULGARI E, et al.Clonal spread of KPC -2 carbapenemase -producing Klebsiella pneumoniae strains in Greece[J]. Journal of Antimicrobial Chemotherapy, 2009, 64(2): 348-52.
[2] European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe[M].Stockholm: European Centre for Disease Prevention and Control,2014.
[3] Centers for disease control and prevention. Facility guidance for control of carbapenem- resistant Enterobacteriaceae (CRE) 2015 update[S/OL].[2020-10-18]. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf.
[4] CHEN L, MATHEMA B, CHAVDA KD, et a1. Carbapenemase producing Klebsiella pneumoniae:molecular and genetic decoding[J]. Trends Microbiol, 2014, 22(12): 686-696.
[5] YANG L, ZHANG ZJ, QIN XS.Carbapenem-resistanct Klebsiella pneumoniae:Resistant mechanisms and risk factors[J]. Chinese Journal of Antibiotics(中国抗生素杂志), 2018, 43(2): 53-58.
[6] TZOUVELEKIS LS, MARKOGIANNAKIS A, PSICHOGIOU M, et al.Carbapenemases in Klebsiella pneumoniae and other enterobacteriaceae: an evolving crisis of global dimensions[J]. Clinical Microbiology Reviews, 2012, 25(4):682-707.
[7] SHI Y, HUANG Y, ZHANG TT, et al.Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)[J]. Journal of Thoracic Disease, 2019, 11(6): 2581-2616.
[8] PAUL M, CARMELI Y, DURANTE-MANGONI E, et al.Combination therapy for carbapenem-resistant Gram-negative bacteria[J]. Journal of Antimicrob Chemother, 2014, 69:2305-2309.
[9] Chinese Society of Hematology, Chinese Medical Association, Chinese Hematology Association, Chinese Medical Doctor Association.Management of Carbapenem- resistant Enterobacteriaceae(CRE) infection in patients with hematological malignancies: Chinese consensus(2020)[J]. Chinese Journal of Hematology(中华血液学杂志), 2020, 41(11): 881-889.
[10] SHIELDS RK, NGUYEN MH, CHEN L, et al. Ceftazidime-avibactamis superior to other treatment regimens against carbapenem-resistant Klebsiella pneumonia bacteremia[J]. Antimicrobial Agents and Chemotherapy, 2017, 61(8):AAC.00883-17.
[11] MARIO T, MARIA TE, GIUSEPPE DRF, et al.Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicenter study[J]. J Antimicrob Chemother, 2015, 70(7): 2133-2143.
[12] DAIKOS GL, MARKOGIANNAKIS A.Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?[J]. Clin Microbiol Infect, 2011, 17(8): 1135-1141.
[13] Highlights of prescribing information. Center For Drug Evaluation And Research, U.S. Food and Drug Administration[EB/OL].(2019-03)[2021-01-20].https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf.
[14] SHIRLEY M.Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections[J]. Drugs, 2018, 78(5): 675-692.
[15] MERDJANH, RANGARAJU M, TARRAL A.Safety and pharmacokinetics of single and multiple ascending doses of avibactamalone and in combination with ceftazidimein healthy male volunteers: results of two randomized, placebo-controlled studies[J]. Clinical Drug Investigation, 2015, 35(5): 307-317.
[16] HAWKEY PM, WARREN RE, LIVERMORE DM, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party?[J]. Journal of Antimicrobial Chemotherapy, 2018, 73(suppl_3): iii2-iii78.
[17] HU X, ZHANG YM, LIU X, et al.Investigation and suggestion on labeling of 75 instructions for intravenous infusion anti-infective drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 168-170.
[18] Microbiology/Virology Review(s). Center For Drug Evaluation And Research, U.S. Food and Drug Administration[EB/OL].(2019-09-25)[2021-01-15].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206494Orig1s000CllinPharmR.pdf.
[19] CAPONE A, GIANNELLA M, FORTINI D, et al.High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality[J]. Clinical Microbiology and Infection, 2013, 19(1): E23-E30.
[20] ZHOU R, CHENG ZZ.Pharmacists’participation in the treatment of a patient with compiicated abdominai infection secondary to invasive fungai infection[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(2):106-110.